Surufatinib

DB15106InvestigationalSmall molecule

Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Chemical structure of Surufatinib
Mechanism
Curator reviewed
Formula / weight
C24H28N6O3S · 480.59 g/mol (avg)
Also known as
SULFATINIB
Code names
HMPL-012

Resolves to

Compound
UNIIB2K5L1L8S9CAS1308672-74-3
Clinical / RWD
ATCL01EX24
Structure
InChIKeyTTZSNFLLYPYKIL-UHFFFAOYSA-NSMILESCN(C)CCNS(=O)(=O)CC1=CC(NC2=NC(OC3=CC4=C(NC(C)=C4)C=C3)=CC=N2)=CC=C1
Targets
P11362FGFR1P07333CSF1RP35916FLT4P35968KDRP17948FLT1

What you can answer from here — as of June 15, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
103Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
10+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Surufatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In